Citeline Podcasts

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs discuss potential takeaways from the Trump Administration floating ophthalmologist, entrepreneur and Fox News contributor Houman David Hemmati as the next potential Center for Biologics Evaluation and Research director (:34), as well as the appointment of US Food and Drug Administration Principal Deputy Commissioner Sara Brenner to a position in the Health and Human Services Department (8:30). They also consider whether the FDA’s approach to adding an indication for leucovorin could be more widely used in the rare disease space (14:08) and new guidance for the agency’s plausible mechanism pathway (22:50). #pharma #business More On These Topics From The Pink Sheet New CBER Director Candidate Could Signal Industry Cred Important Again: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/new-cber-director-candidate-could-signal-industry-cred-important-again-ZDJ4ECR4QNDBPBRTKNHD2B5R24/ US FDA’s Principal Deputy Commissioner Moving To HHS As Senior Counselor For Public Health: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-principal-deputy-commissioner-moving-to-hhs-as-senior-counselor-for-public-health-C64ZB6WRTNEJ7MC7I3ZY3KNP6I/ US FDA’s Literature-Based Leucovorin Approval May Offer A Rare Disease Template: https://insights.citeline.com/pink-sheet/rare-diseases/us-fdas-literature-based-leucovorin-approval-may-offer-a-rare-disease-template-Z34IYMFF35ENVJXV4N4ZT4GG6Q/ US FDA To Clarify Plausible Mechanism Framework With Genome Editing Guidances, Workshop: https://insights.citeline.com/pink-sheet/advanced-technologies/cell-and-gene-therapies/us-fda-to-clarify-plausible-mechanism-framework-with-genome-editing-guidances-workshop-QTWKR3NCXJFJNKCOE3BTBSW4K4/

김윤철 삼성바이오에피스 상무는 Scrip과의 인터뷰에서 ADC 및 기타 신약개발 전략 등에 대해 이야기했습니다. 이 기사를 요약한 내용입니다. (AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다) Story link: https://insights.citeline.com/scrip/focus-on-asia/south-korea/samsung-bioepis-sharpens-differentiation-strategy-as-global-adc-market-matures-T4E7D2U4DZFJFIERGRWM7PECTM/

Join Scrip and The Pink Sheet's Tokyo-based team Lisa Takagi and Ian Haydock for a roundup of key commercial and policy/regulatory developments in Japan's biopharma market over the first few months of this year, including some important corporate divestments and new product approvals. Also a look at how the Iran war is impacting the healthcare sector in the country.

How can small biotechs tap billion‑dollar AI models without giving up their data? David Wild talks with Eli Lilly's Aliza Apple about Lilly TuneLab, a federated learning platform that lets companies use Lilly’s in-house drug discovery models while keeping their IP and datasets fully private. They dive into early use cases in ADMET and antibody developability, what early-stage users actually do in their first 90 days, and how shared models could reshape the economics of drug R&D.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月10日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 特朗普政府对部分药品及原料药征收100%关税；美国关税政策给获美批准的中国药品带来阴影； 吉利德收购Tubulis；深入解析Neurocrine对Soleno的收购要约；以及对第一季度并购活动的分析。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-O7KEIWGMHBCLZBHKJPKGHOZYPE/

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 10, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Trump’s 100% tariffs and pharma; US tariffs loom over US-approved Chinese drugs; Gilead’s Tubulis buy-out; a closer look at Neurocrine’s Soleno bid; and an analysis of Q1 M&A. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-O7KEIWGMHBCLZBHKJPKGHOZYPE/

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman and Editor-in-Chief Nielsen Hobbs discuss the details of the US Food and Drug Administration’s labeling update for leucovorin (:41), including GSK’s subsequent move to re-withdraw the application (19:45). They also grade the tenure of Steve Ubl as he prepares to leave as Pharmaceutical Research and Manufacturers of America president and CEO (21:02) and consider what the organization may seek in its next leader (27:07). #pharma #business More On These Topics From The Pink Sheet A Regulatory Pathway Of One: US FDA’s Wellcovorin Approval Would Be Hard To Scale: https://insights.citeline.com/pink-sheet/rare-diseases/a-regulatory-pathway-of-one-us-fdas-wellcovorin-approval-would-be-hard-to-scale-BHEAMFMG5BDJHJY5K6Z5OJF22A/ Outgoing PhRMA CEO Ubl Fought, Shaped Policies and Politics Around Price Controls: https://insights.citeline.com/pink-sheet/r-and-d/breaking-phrma-ceo-steve-ubl-leaving-later-this-year-2FNX2D5LE5GC3J2HARTZPHZDB4/

Israel has been a prolific source of biotech and AI-driven startups for years, but can it compete as a strategic R&D partner for global pharma? Mati Gill, CEO of AION Labs, makes the case that it can. AION's venture studio model brings together AstraZeneca, Merck KGaA, Pfizer and Teva under one roof to co-create AI-native drug discovery companies, and its portfolio is already producing results: CombinAbleAI, one of its startups, was acquired by insitro less than two years after it was founded. Gill talks about Israel's genuine strengths in science and technology, the structural gaps that still need closing, and why three years of operating through an active war may actually be a point in the ecosystem's favour for risk-conscious partners. Recorded, with some interruptions, from Tel Aviv.

Andrew Parker, CEO at Step Pharma, outlined the company’s “pipeline in a product” strategy as it seeks to develop a targeted approach to blood cancers and solid tumors by inhibiting CTSP1 enzyme. #clinicalstrategy #oncology

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月03日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 礼来收购Centessa的意义；Apellis为Biogen注入新能力；中国企业在肥胖症领域取得的快速进展；口服药物在肥胖症治疗中占据主导地位；以及全球制药研发管线规模的缩减。 Story link: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HFN7H2ELQBBRHHFQQ2AYFBMXNM/

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 3, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HFN7H2ELQBBRHHFQQ2AYFBMXNM/

In this episode of the China biopharma English-language podcast, Xu Hu talks about recently China releasing two guidelines related to CAR-T therapies within a month and the strategic position that the country puts its cell therapy sector. The Pink Sheet stories related to this episode: CAR-T Guidelines Signal China’s Next Phase Of Cell Therapy Regulatory System Building CAR-Ts Win Big In New China Drug Coverage Lists

A legal firm’s perspective on how the UK should evolve its medtech regulatory system, global harmonization and opportunities to embed best practice AI.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年3月27当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 默克公司力推Terns及其他交易；勃林格殷格翰对欧洲创新环境不佳的警示；科伦与默克的协议如何改变了中国的交易格局；神经科学研发重振旗鼓；以及美国新的低密度脂蛋白胆固醇（LDL-C）指南与药物成本。

In this episode of HBW Insight’s Over the Counter, we’re digging into one of the most talked‑about themes in consumer health right now: longevity. We’re joined by Magda Starula, Health and Beauty Research Analyst at Euromonitor International, to unpack what “healthy longevity” really means, and why it’s quickly moving from niche concept to mainstream commercial opportunity for OTC. We explore how the focus is shifting from simply living longer to staying healthier for longer, what that means across different life stages, and where consumer healthcare brands are best placed to win.

Audio roundup of selected biopharma industry content from Scrip over the business week ended Mar.27, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Merck’s case for Terns and more deals; Boehringer’s warning on innovation-unfriendly Europe; how Kelun-Merck pact changed China deal-making; Story Link : https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KYHAYYDQKVF2BPXKKKMZ2J4GA4/

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider US Food and Drug Administration Commissioner Martin Makary’s first year in office, including the issues that shaped his tenure (:32), his biggest policy accomplishments (14:12), issues that could emerge in his second year (19:35), and when Makary’s term could end (22:52). #pharma #business #FDA More On These Topics From The Pink Sheet US FDA Commissioner Makary’s ‘Bold’ Year 1 Reforms Clouded By Staff Churn, Process Issues: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-commissioner-makarys-bold-year-1-reforms-clouded-by-staff-churn-process-issues-BM6PHO3AWNBWXHL5UAJI4YE7TQ/ His Own Words: FDA Commissioner Martin Makary On His First Year Achievements And Challenges: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/his-own-words-fda-commissioner-martin-makary-on US FDA Commissioner Martin Makary’s Eventful First Year: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-commissioner-martin-makarys-eventful-first-year-5KU6I3ATTBHIDKFLBKZDWJ5XHA/

Lupin’s CEO Vinita Gupta and managing director Nilesh Gupta speak with Citeline’s senior editor Vibha Ravi about their plans for first-in-class and best-in-class assets including GLP-1 receptor agonists, the defining influence of their father D B Gupta on them, as well as the company’s ethos and future growth strategy.

Lupin’s CEO Vinita Gupta and managing director Nilesh Gupta speak with Citeline’s senior editor Vibha Ravi about their plans for first-in-class and best-in-class assets including GLP-1 receptor agonists, the defining influence of their father D B Gupta on them, as well as the company’s ethos and future growth strategy.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年3月20日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 今年将有众多重磅药物失去市场主导地位; 司美格鲁肽在印度的命运；跨国药企不再满足于单纯的中国授权； Almirall瞄准中国皮肤科资产；欧盟被敦促恢复生物制药竞争力。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KZ6RVPJK6BAADJKFNBUNOTMB6M/ Playlist: on.soundcloud.com/gnr7PaOwflNKiAO7QX